USPTO Examiner ARNOLD ERNST V - Art Unit 1613

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19094018TESTOSTERONE ENHANCING COMPOSITIONS AND METHODSMarch 2025January 2026Allow1020YesNo
19076524INHIBITION OF CANCER CELL VIABILITYMarch 2025June 2025Allow300NoNo
19068391ORGANIC BIOMATERIAL FOR BONE AND JOINT REPLACEMENTMarch 2025May 2025Allow200NoNo
19061465FORMULATIONS OF BENDAMUSTINEFebruary 2025May 2025Allow310NoNo
18980349MICROPARTICLE FORMULATIONS FOR INTRAVENOUS THERAPY AND METHODS FOR THEIR MANUFACTURE AND USEDecember 2024September 2025Allow920NoNo
18923418CENTANAFADINE PHARMACEUTICAL FORMULATIONS, AND METHODS OF MAKING AND USING SAMEOctober 2024March 2025Allow510YesNo
18783428COMPOSITIONS CONTAINING CANNABINOID NANOPARTICLESJuly 2024March 2026Allow1900NoNo
18739378SOLVENT-BASED METHOD FOR MAKING NANOCOMPOSITE PHARMACEUTICAL MATERIALJune 2024August 2024Allow200NoNo
18658338INTRADIALYTIC USE OF SODIUM NITRITEMay 2024January 2026Allow2010NoNo
18646171FORMULATIONS OF BENDAMUSTINEApril 2024August 2024Allow410NoNo
18646329FORMULATIONS OF BENDAMUSTINEApril 2024April 2025Allow1220NoNo
18637263COMPOSITIONS, FORMULATIONS AND METHODS FOR STIMULATING RESPIRATIONApril 2024December 2025Abandon2021YesNo
18630735METHOD FOR MANUFACTURING BONE-REGENERATION MATERIAL COMPRISING BIODEGRADABLE FIBERS BY USING ELECTROSPINNING METHODApril 2024March 2026Allow2300NoNo
18598402Devices for Treating Diseases and ConditionsMarch 2024May 2024Allow200YesNo
18599125METHOD OF TREATING DISEASESMarch 2024January 2025Allow1020YesNo
18599127METHOD OF TREATING DISEASESMarch 2024January 2025Allow1020NoNo
18444175ENHANCED IMMUNE RESPONSE UPON TREATMENT WITH NITRIC OXIDEFebruary 2024April 2025Abandon1410NoNo
18427459CENTANAFADINE PHARMACEUTICAL FORMULATIONS, AND METHODS OF MAKING AND USING SAMEJanuary 2024July 2024Allow610NoNo
18426704TREATING AND PREVENTING DISEASE WITH TMA AND TMAO LOWERING AGENTSJanuary 2024April 2025Abandon1510NoNo
18421265NITRIC OXIDE THERAPIESJanuary 2024January 2026Allow2420NoNo
18580703BIOMIMETIC, REACTIVE OXYGEN SPECIES-DETONABLE NANOCLUSTERS FOR ANTIRESTENOTIC THERAPYJanuary 2024January 2026Allow2410NoNo
18411482IMMUNISATION OF LARGE MAMMALS WITH LOW DOSES OF RNAJanuary 2024November 2025Allow2200NoNo
18408463METHODS OF USE OF EMULSION FORMULATIONS OF APREPITANTJanuary 2024January 2025Allow1320NoNo
18405512COMPOSITION USED FOR THERAPEUTIC TREATMENT OF SKIN DISEASEJanuary 2024April 2025Abandon1510NoNo
183917663D Printed Scaffold Structures and Methods of FabricationDecember 2023September 2025Allow2121YesNo
18542954PHARMACEUTICAL COMPOSITION FOR NASAL DELIVERYDecember 2023February 2025Allow1411NoNo
18519530POLYMER PARTICLES FOR NEUTROPHIL INJURYNovember 2023January 2025Allow1310NoNo
18516480SELF-EMULSIFYING DRUG DELIVERY (SEDDS) FOR OPHTHALMIC DRUG DELIVERYNovember 2023August 2025Abandon2111NoNo
18514644METHOD OF TREATING DISEASESNovember 2023December 2025Abandon2410NoNo
18498259FORMULATIONS OF BENDAMUSTINEOctober 2023October 2025Abandon2310NoNo
18556796COMPOSITIONS AND METHODS RELATED TO MEGAKARYOCYTE-DERIVED EXTRACELLULAR VESICLES FOR FANCONI ANEMIAOctober 2023September 2025Allow2300NoNo
18556173INHIBITION OF CRYSTALLIZATION AND/OR BIOFILM FORMATION ON AN INDWELLING URINARY CATHETEROctober 2023March 2026Allow2920YesNo
18373603Medical Implants And Methods Of ManufactureSeptember 2023August 2024Allow1100NoNo
18367876COMPOSITIONS AND METHODS FOR PROMOTING CELLULAR METABOLIC FITNESSSeptember 2023February 2026Abandon2920NoYes
18239715Nanoparticles Containing a Taxane and their UseAugust 2023May 2025Allow2010NoNo
18457210THERAPEUTIC AGENT PREPARATIONS FOR DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICEAugust 2023July 2025Abandon2310NoNo
18453988PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF OPHTHALMIC CONDITIONSAugust 2023April 2025Allow2011NoNo
18235817COMPOSITION FOR HYDRATION AND REDUCING THE EFFECTS OF ACOHOLAugust 2023August 2025Allow2400NoNo
18451593MINIMIZING AGGLOMERATION OF DRUG PARTICLE COATING MATERIAL DURING STORAGE TO STABILIZE DISINTEGRATION TIMES OF PHARMACEUTICAL PRODUCTSAugust 2023April 2025Allow2010NoNo
18448809MICROBIOLOGICAL TRANSPORT MEDIUM AND METHODS OF USING THE SAMEAugust 2023March 2025Abandon1911NoNo
18362813METALLO-LIOTHYRONINEJuly 2023February 2025Abandon1910NoNo
18224232BENDAMUSTINE SOLID DISPERSIONS AND CONTINUOUS INFUSIONJuly 2023May 2025Abandon2211NoNo
18221143Powder Blend Processability Improvements Through Minimal Amounts Of Synergistically Selected Surface Coating AgentsJuly 2023April 2024Allow920YesNo
18219623ENCAPSULATED PROBIOTICJuly 2023June 2025Allow2340NoNo
18267783USE OF TWO-DIMENSIONAL NANOMATERIAL IN INHIBITION OF CORONAVIRUSJune 2023February 2026Allow3220NoNo
18329399INSOLUBLE TRANSDERMAL MICRONEEDLE PATCH, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOFJune 2023September 2023Allow300NoNo
18265066HOMOGENEOUS PHARMACEUTICAL EXCIPIENT SODIUM STEARYL FUMARATE WITH FLAKY STRUCTURE AND PREPARATION METHOD THEREOFJune 2023November 2025Allow2910NoNo
18204728CENTANAFADINE PHARMACEUTICAL FORMULATIONS, AND METHODS OF MAKING AND USING SAMEJune 2023October 2023Allow510NoNo
18322657Product and method for increasing uridine concentration in blood plasmaMay 2023January 2026Abandon3201NoNo
18313924SODIUM PERCARBONATE DISSOLVING BATH PRODUCT FORMULATIONMay 2023October 2025Abandon2921NoNo
18307184DEVICE POSITIONABLE IN THE UTERINE CAVITY AND METHOD OF TREATMENT THEREOFApril 2023July 2024Allow1510NoNo
18302899COMPOSITIONS AND METHODSApril 2023March 2026Abandon3501NoNo
18295863METHOD FOR FORMING A SILVER-CONTAINING NANOCOMPOSITE PHARMACEUTICAL COMPOUNDApril 2023May 2024Allow1400NoNo
18127862LIPOSOME ENCAPSULATING CYSTEAMINE AND RESVERATROL IN SEPARATE COMPARTMENTSMarch 2023June 2025Abandon2740NoNo
18127633PHARMACEUTICAL LOTION OR SALVE UTILIZING MIXED METAL HYDROXIDE ANTIMICROBIAL CHARGED PARTICLESMarch 2023August 2023Allow410YesNo
18190839SOLUTION FOR ORAL ADMINISTRATIONMarch 2023October 2024Abandon1810NoNo
18186304METHOD OF TREATING SPINAL DISKMarch 2023July 2024Allow1610NoNo
18185689COMPOSITIONS AND METHODS FOR PREVENTING AND/OR AMELIORATING ORGAN-SPECIFIC AUTOIMMUNE DISEASESMarch 2023January 2026Abandon3410NoNo
18120762Lyophilized Formulations of AAV Drug ProductsMarch 2023February 2026Allow3511NoNo
18044969METHODS FOR PREPARATION OF A TERMINALLY STERILIZED HYDROGEL OR COLLOIDAL SUSPENSION DERIVED FROM EXTRACELLULAR MATRIX, AND USES THEREOFMarch 2023January 2026Allow3410NoNo
18115789ANTIBACTERIAL SURFACE OF METAL-ORGANIC FRAMEWORK-CHITOSAN COMPOSITE FILMSMarch 2023February 2025Allow2320YesNo
18174549OXYGEN-CONTAINING PARTICLES, MANUFACTURING METHOD THEREFOR, AND USE THEREOFFebruary 2023December 2025Abandon3410NoNo
18022193COMPOUNDS FOR PREVENTION OR TREATMENT OF NEURODEGENERATIVE DISORDERSFebruary 2023July 2025Allow2900NoNo
18092569INTRADIALYTIC USE OF SODIUM NITRITEJanuary 2023February 2024Allow1300YesNo
18086506METHOD OF MANUFACTURING A BIOIMPLANTDecember 2022October 2024Allow2220YesNo
18081238FORMULATIONS OF BENDAMUSTINEDecember 2022October 2023Allow1030YesNo
18081251FORMULATIONS OF BENDAMUSTINEDecember 2022November 2023Allow1130YesNo
18072473CENTANAFADINE PHARMACEUTICAL FORMULATIONS, AND METHODS OF MAKING AND USING SAMENovember 2022July 2023Allow810NoNo
18070134METHOCARBAMOL COMPOSITIONS AND RELATED METHODSNovember 2022July 2024Allow2010NoNo
17999870METHODS OF TREATMENT OF VIRAL DISEASESNovember 2022December 2025Abandon3610NoNo
17991157METHODS OF PRODUCING AN OSTEOINDUCTIVE CALCIUM PHOSPHATE MATERIAL FOR BONE GRAFTINGNovember 2022July 2024Abandon2010NoNo
17999194CGAS INHIBITING TRIAZOLOPYRIMIDONE DERIVATIVESNovember 2022August 2025Allow3310NoNo
17987989DEVICES AND METHODS FOR DELIVERY OF SUBSTANCES TO ANIMALSNovember 2022May 2024Allow1811YesNo
17987983DEVICES AND METHODS FOR DELIVERY OF SUBSTANCES TO ANIMALSNovember 2022October 2024Allow2331YesNo
18054082POLYMER LUNG SURFACTANTSNovember 2022July 2025Allow3230NoNo
17978700Method for Coating Pharmaceutical SubstratesNovember 2022December 2023Allow1430YesNo
17922223CRYSTAL OF TRIFLUOROMETHYL/CHLORO DISUBSTITUTED SULFONAMIDE SELECTIVE BCL-2 INHIBITOROctober 2022October 2025Allow3610NoNo
17972172Pharmaceutical Formulation with Improved Solubility and BioavailabilityOctober 2022May 2025Allow3130NoNo
17966092IMPLANTS INCLUDING MODIFIED DEMINERALIZED CORTICAL BONE FIBERS AND METHODS OF MAKING SAMEOctober 2022December 2024Allow2620NoNo
17965209CERAMIC COMPOSITION COMPRISING ANTIMICROBIAL GLASS COMPOSITIONOctober 2022November 2025Allow3730NoNo
18045377SYSTEMS AND METHODS TO REPAIR TISSUE DEFECTSOctober 2022January 2025Allow2730YesNo
17962381COMPOSITIONS AND METHODS FOR PROMOTING CELLULAR METABOLIC FITNESSOctober 2022January 2024Abandon1621YesNo
17914587THERAPEUTIC STRATEGIES TO MANAGE FACIAL CONTRACTURES POST INJURYSeptember 2022December 2025Abandon3910NoNo
17945618MOLDABLE ORTHOPEDIC COMPOSITION WITH ANTI-WASHOUT PROPERTYSeptember 2022January 2026Allow4010NoNo
17930716Zeaxanthin Formulations With Additional Ocular-Active Nutrients, For Protecting Eye Health And Treating Eye DisordersSeptember 2022December 2023Abandon1620YesYes
17901258Cartilage Regeneration Using Injectable, In Situ Polymerizable Collagen Compositions Containing Chondrocytes or Stem CellsSeptember 2022October 2023Allow1421NoNo
17895347SOLID DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC) COMPOSITIONSAugust 2022May 2024Allow2110NoNo
17819934METHOD FOR PRODUCING A DRUG DELIVERY SYSTEMAugust 2022January 2025Allow2920NoNo
17819675CELLULAR BONE GRAFTS, AND METHODS OF MANUFACTURE AND USEAugust 2022November 2024Allow2730NoNo
17819942METHOD FOR PRODUCING A DRUG DELIVERY SYSTEMAugust 2022January 2025Allow3020NoNo
17819941METHOD FOR PRODUCING A DRUG DELIVERY SYSTEMAugust 2022January 2025Allow3020NoNo
17819940METHOD FOR PRODUCING A DRUG DELIVERY SYSTEMAugust 2022January 2025Allow2920NoNo
17819938METHOD FOR PRODUCING A DRUG DELIVERY SYSTEMAugust 2022January 2025Allow2920NoNo
17879557METHOD OF TREATING DISEASESAugust 2022October 2022Allow210NoNo
17803470Processes for Breaching Blood-Brain BarrierJuly 2022January 2024Abandon1810NoNo
17859820SHAPE CHANGING DRUG DELIVERY DEVICES AND METHODSJuly 2022December 2023Allow1700YesNo
17858404NOVEL PHARMACEUTICAL FORMULATIONS CONTAINING INDIRUBIN AND DERIVATIVES THEREOF AND METHODS OF MAKING AND USING THE SAMEJuly 2022February 2025Abandon3121NoNo
17428273A CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION OF SELEXIPAG OR IT'S ACTIVE METABOLITEJuly 2022July 2025Allow4820YesNo
17808390PHARMACEUTICAL COMPOSITION COMPRISING A POTENT INHIBITOR OF URAT1June 2022March 2024Abandon2110NoNo
17840002PHARMACEUTICAL COMPOSITIONS COMPRISING ZINCJune 2022April 2024Abandon2210NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner ARNOLD, ERNST V.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
62
Examiner Affirmed
51
(82.3%)
Examiner Reversed
11
(17.7%)
Reversal Percentile
29.6%
Lower than average

What This Means

With a 17.7% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
191
Allowed After Appeal Filing
20
(10.5%)
Not Allowed After Appeal Filing
171
(89.5%)
Filing Benefit Percentile
13.8%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 10.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner ARNOLD, ERNST V - Prosecution Strategy Guide

Executive Summary

Examiner ARNOLD, ERNST V works in Art Unit 1613 and has examined 1,237 patent applications in our dataset. With an allowance rate of 51.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 30 months.

Allowance Patterns

Examiner ARNOLD, ERNST V's allowance rate of 51.3% places them in the 13% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by ARNOLD, ERNST V receive 2.44 office actions before reaching final disposition. This places the examiner in the 71% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by ARNOLD, ERNST V is 30 months. This places the examiner in the 58% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +11.4% benefit to allowance rate for applications examined by ARNOLD, ERNST V. This interview benefit is in the 46% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 14.4% of applications are subsequently allowed. This success rate is in the 10% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 29.5% of cases where such amendments are filed. This entry rate is in the 42% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 23.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 28% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 45.1% of appeals filed. This is in the 11% percentile among all examiners. Of these withdrawals, 54.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.

Petition Practice

When applicants file petitions regarding this examiner's actions, 56.1% are granted (fully or in part). This grant rate is in the 58% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.9% of allowed cases (in the 66% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.9% of allowed cases (in the 60% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.